Effectiveness of anti-interleukin 23 biologic drugs in psoriasis patients who failed anti-interleukin 17 regimens. A real-life experience

Research output: Contribution to journalArticlepeer-review

Abstract

Among the most recent biologic drugs available for psoriasis therapy, those targeting interleukin-17 (secukinumab and ixekizumab) or its receptor (brodalumab) have been shown to be quickly effective. However, in those patients who failed one or more of the above-cited drugs, real-life data on the effectiveness of switching to one anti-interleukin-23 biologic (guselkumab, risankizumab, or tildrakizumab) are very scarce. Here, we report our experience in treating 12 multi-failure psoriatic patients, prospectively followed-up over 6 months, who showed a significant improvement in their psoriasis after switching from an anti-interleukn-17 to an anti-interleukin-23 drug.

Original languageEnglish
JournalDermatologic Therapy
DOIs
Publication statusAccepted/In press - 2020

Keywords

  • anti-interleukin 17
  • anti-interleukin 23
  • biologics
  • psoriasis
  • switch

ASJC Scopus subject areas

  • Dermatology

Fingerprint

Dive into the research topics of 'Effectiveness of anti-interleukin 23 biologic drugs in psoriasis patients who failed anti-interleukin 17 regimens. A real-life experience'. Together they form a unique fingerprint.

Cite this